Filing identity and reporting period
Important discrepancy: The supplied filing is Aquinox Pharmaceuticals, Inc.’s Form 10-K for the fiscal year ended December 31, 2018, filed March 7, 2019. It is not a Neurogene Inc. filing. The filing reports annual results, with separate quarterly data for 2018.
Business context
Aquinox was a clinical-stage pharmaceutical company. Its Phase 3 Leadership 301 trial of rosiptor for interstitial cystitis/bladder pain syndrome failed its primary endpoint in June 2018; the company halted further rosiptor development. After two restructurings, headcount fell from 56 to eight. At the filing date, Aquinox had no product candidates in clinical development or identified for clinical development.
Financial results and liquidity
Amounts are in U.S. dollars; annual results are for years ended December 31.
| Metric | 2018 | 2017 | Change / context |
|---|---|---|---|
| Revenue | $25.0 million | $0 | Entirely the non-refundable Astellas upfront payment; no product-sales revenue |
| Research and development expense | $41.8 million | $36.3 million | Rose, including $9.0 million of restructuring charges |
| General and administrative expense | $15.8 million | $14.9 million | Rose, including $1.1 million of restructuring charges |
| Total operating expenses | $57.6 million | $51.1 million | Higher by $6.5 million |
| Operating loss | $32.6 million | $51.1 million | Improved with the one-time license revenue, despite higher expenses |
| Net loss | $31.6 million | $50.2 million | Loss per share was $1.34 versus $2.14 |
| Cash and cash equivalents | $76.9 million | $52.0 million | Short-term investments were zero at 2018 year-end, versus $56.1 million in 2017 |
| Working capital | $72.5 million | $97.9 million | Declined |
| Total liabilities | $4.9 million | $11.4 million | No material debt balance is reported |
Cash used in operating activities was $31.6 million, compared with $44.7 million in 2017. The company reported $72.7 million of stockholders’ equity and a $230.1 million accumulated deficit at year-end. Gross margin is not separately presented; reported revenue was a license payment rather than product sales.
Material changes, outlook, and risks
- Astellas paid Aquinox a $25.0 million upfront fee under a rosiptor license and collaboration agreement. After the Phase 3 failure, Astellas terminated the agreement effective November 8, 2018; the payment was non-refundable and recognized as 2018 revenue. Potential milestones and royalties are uncertain and the filing does not establish expected future receipts.
- Restructuring charges were approximately $10.4 million across R&D, G&A, and miscellaneous expenses. The filing estimates that the company’s existing capital resources would fund operations for at least 12 months from the filing’s outlook date, subject to risks and assumptions.
- Management and the board were evaluating mergers, licenses, acquisitions, and whether research-stage compounds could be advanced. If suitable candidates could not be identified or acquired, the board might consider returning capital to stockholders and dissolving the business.
- Key risks include the lack of a clinical pipeline, continuing operating losses and cash use, the need for future financing, execution and dilution risks from a merger or acquisition, and reduced staffing and internal development capabilities. The company stated it had no material legal proceedings and no off-balance-sheet arrangements.
- Fourth-quarter 2018 revenue was zero and net loss was $4.9 million, or $0.20 per share, versus a fourth-quarter 2017 net loss of $16.3 million, or $0.69 per share.
Important facts for investors to verify
- Confirm the issuer: this document identifies Aquinox Pharmaceuticals, Inc., not Neurogene Inc.
- Review the audited financial statements and cash-flow details, including the distinction between cash and cash equivalents and short-term investments.
- Assess cash burn and runway against the company’s stated 12-month estimate, and determine whether financing or asset transactions occurred after the filing date.
- Verify the status and value of any merger, licensing, acquisition, or dissolution discussions; the filing provides no committed transaction or replacement clinical candidate.
- Review restructuring liabilities, remaining lease commitments, and the potential dilution and ownership terms of any future transaction.